Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.

ABSTRACT

This study examined the effects of regorafenib (Reg) on progression-free survival (PFS), overall survival (OS), and adverse events (AEs) in metastatic colorectal cancer (mCRC) patients who underwent targeted treatment and chemotherapy. Reg was administered as a third-line treatment to 84 patients who had undergone 2 rounds of chemotherapy and targeted therapy and subsequently experienced progression. Treatment was initiated with a daily dose of 80 or 120 mg, based on the patient's ability to tolerate the medication, which was increased to 160 mg/day. The median PFS with Reg was 4 ±â€…0.2 months, while the median OS was 9 ±â€…1.2 months. When compared to patients who started Reg treatment at 80 mg, patients starting at 160 mg had longer median PFS and OS (PFS6 ±â€…2.1 months vs 4 ±â€…0.2 months; P = .05; OS13 ±â€…0.7 months vs 6 ±â€…1.3 months; P = .069). Patients with right-sided colon cancer who received Reg as third-line therapy had a significantly longer mPFS than those with left-sided colon cancer (8 months ±â€…4 vs 4 months ±â€…0.3, P = .039). Patients with KRAS mutations had a prolonged mPFS than those with panRAS-wild type (6 ±â€…1.6 months vs 4 ±â€…0.3 months, P = .06). The mPFS contribution in the BRAF mutant subgroup with poor prognosis is promising, as it is similar to that of patients without BRAF mutations (4 months ±â€…0.8 × 4 months ±â€…0.5, P = .74). The most common AEs reported were elevated liver enzyme levels and dermatological toxicities.